Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Two-Session Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an 16448 in Healthy Males With Premature Ejaculation.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Aug 2023
Price :
$35
*
At a glance
- Drugs Retosiban (Primary)
- Indications Premature ejaculation
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 27 May 2009 New trial record